

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: July 21, 2008 Signature:   
(Marshall P. Byrd)

Docket No.: 29853/37704A  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Joseph Senesac

Application No.: 10/649,974

Confirmation No.: 7068

Filed: August 27, 2003

Art Unit: 1651

For: CHROMATOGRAPHIC METHODS FOR  
ADENOVIRUS PURIFICATION

Examiner: L. B. Lankford

### **SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT (SIDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)). In accordance with 37 CFR 1.97(e), each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. In particular, each reference cited herein was first cited in a Supplementary Search Report from the European Patent Office dated June 17, 2008 (*i.e.*, less than three months prior to the filing of the instant SIDS).

Applicant submits herewith copies of non-patent literature (listed as C198 and C199) in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art."

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

No fees are believed due in connection with this paper; however if it is determined that fees are due, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 29853/37704A.

Dated: July 21, 2008

Respectfully submitted,

By   
Marshall P. Byrd  
Registration No.: 62,454  
MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Attorney for Applicant